Econ Financial Services Corp Buys New Position in Biogen Inc. $BIIB

Econ Financial Services Corp bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,946 shares of the biotechnology company’s stock, valued at approximately $694,000.

Other institutional investors have also added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Biogen during the 2nd quarter worth $25,000. Accredited Wealth Management LLC increased its stake in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares in the last quarter. WFA of San Diego LLC bought a new position in Biogen in the 2nd quarter worth $32,000. True Wealth Design LLC raised its holdings in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares during the period. Finally, GoalVest Advisory LLC bought a new position in Biogen in the 4th quarter worth $35,000. 87.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BIIB has been the subject of several recent research reports. HC Wainwright boosted their price target on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 9th. Wedbush raised their price objective on Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research note on Monday, February 9th. UBS Group assumed coverage on Biogen in a research report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective on the stock. Oppenheimer boosted their price objective on Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, January 30th. Finally, Barclays began coverage on shares of Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Biogen currently has a consensus rating of “Hold” and an average target price of $205.31.

Biogen Trading Down 2.3%

Shares of Biogen stock opened at $183.33 on Wednesday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company has a market capitalization of $26.91 billion, a P/E ratio of 20.81, a P/E/G ratio of 1.49 and a beta of 0.15. The company has a fifty day moving average of $186.19 and a 200 day moving average of $170.98.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the firm earned $3.44 earnings per share. The business’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.18% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose regimen of SPINRAZA, which could bolster Biogen’s rare‑disease revenue and defend market share in spinal muscular atrophy; the approval was cited as a catalyst for an earlier share pop. US FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Biogen agreed to buy Apellis for about $5.6B, gaining commercial drugs (EMPAVELI®, SYFOVRE®) and entry into nephrology and ophthalmology — a strategic move to diversify beyond MS and lift long‑term growth expectations. Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio
• Neutral Sentiment: Analysts largely kept Hold/neutral ratings after the news — firms note the approvals and deal are constructive but that execution, MS franchise erosion and competition limit near‑term upside. Spinraza HD approval supports but does not transform outlook
• Negative Sentiment: Market reaction is mixed-to-negative for BIIB: Apellis stock more than doubled on the buyout (market sees strong value in Apellis), while Biogen shares fell as investors weigh the $5.6B cash outlay, premium paid and contingent CVR payments. Apellis Pharma Skyrockets on Biogen Deal
• Negative Sentiment: Integration and financial risk: analysts and commentary flag potential near‑term pressure on cash and the need to execute launches and cross‑sell acquired products; some view the price as a premium that constrains near‑term EPS benefit. Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.